Sign in
Taking peoplePhase 2/3

A Randomized Controlled Study of the Efficacy and Safety of Lenalidomide in the Treatment of Active IgG4-related Disease

Key facts

Who runs it
Peking Union Medical College Hospital
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 2/3
People taking part
198 people, planned
Started
7 Jul 2025
Expected to end
20 Aug 2028
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • 5mg lenalidomide
  • 10mg lenalidomide
  • Prednisone monotherapy
Record updated
30 December 2025

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Patients aged between 18 and 75 years who meet the 2019 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification criteria for IgG4-RD;
  • Patients with active disease: For patients with initial treatment or relapse after drug withdrawal, active disease is defined as having an IgG4-RD Response Index (RI) of at least 2 points in at least one organ at the time of screening; for those experiencing relapse while on treatment, active disease is defined as having an IgG4-RD RI of at least 3 points in at least one organ at the time of screening;
  • Patients with the clinical subtype of proliferative IgG4-RD;
  • Patients who have no plans for pregnancy within the next 18 months and who agree to use reliable contraceptive measures during the study period;

Who cannot take part

  • Chronic active infection requiring systemic treatment
  • Diagnosed with malignant tumor in the past five years
  • Patients with a history of thrombosis
  • Known to be allergic to lenalidomide or thalidomide
  • Patients with any other medical conditions or for specific reasons judged by the investigator to be ineligible to participate in the study
  • Absolute neutrophil count <1.5×10\^9 /L or platelet count <100×10\^9/L
  • Creatinine clearance less than 60 ml/ min
  • IgG4-RD patients with only fibrotic features
  • Liver function Child-Pugh grade B or above
  • Using biological agents within six months
  • Pregnant or lactating women

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

This trial is currently available in China.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

For patients with active proliferative IgG4-RD, we plan to conduct a 52-week prospective randomized controlled trial to compare the efficacy and safety of 5mg lenalidomide plus prednisone, 10mg lenalidomide plus prednisone, and prednisone alone, so as to find new treatment measures for patients with proliferative IgG4-RD.

The 3 groups in the trial

  • 5mg lenalidomide groupTreatment being tested

    Lenalidomide 5mg/d combined with prednisone, prednisone at an initial dose of 0.6-0.8mg/kg/d for 2-4 weeks, then reduced by 5mg every 1-2 weeks until discontinued (within 24 weeks)

    Treatment: 5mg lenalidomide

  • 10 mg lenalidomide groupTreatment being tested

    Lenalidomide 10mg/ day combined with prednisone, the initial dose of prednisone was 0.6-0.8mg/kg/ day for 2-4 weeks, then 5mg every 1-2 weeks until withdrawal (within 24 weeks).

    Treatment: 10mg lenalidomide

  • Prednisone monotherapy groupExisting treatment, for comparison

    The initial dose of prednisone was 0.6-0.8mg/kg/ day for 2-4 weeks, followed by 5mg every 1-2 weeks until withdrawal (within 24 weeks).

    Treatment: Prednisone monotherapy

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized Controlled Study of the Efficacy and Safety of Lenalidomide in the Treatment of Active IgG4-RD
Criteria questions
Built from NCT07068165, who can take part
Record updated
30 December 2025